BD Recalls Needle Sets After 4 Deaths, 45 Serious Injuries
BDX sits 30% above its 52-week low of $127.536 on light trading volume (0.3× avg).
Summary
BD is voluntarily recalling its intraosseous vascular access system needle sets after receiving 75 complaints, including 45 serious injuries and 4 deaths, all linked to difficulty removing the obturator during resuscitation. The affected products were distributed over nearly two years, from September 2024 to June 2026. This is a significant safety event for a $45B medical device company, with potential regulatory scrutiny and reputational damage. The recall does not affect the powered driver, but the needle sets are critical in emergency care. No prior news in the timeline covers this recall, making it a fresh, material negative development. Watch for FDA classification of the recall and any financial impact disclosures in upcoming filings.
At the time of this announcement, BDX was trading at $165.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $45.6B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.